RTW Investments LP Trims Stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST)

RTW Investments LP trimmed its position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 23.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,506,102 shares of the company's stock after selling 750,000 shares during the period. RTW Investments LP owned approximately 4.70% of Milestone Pharmaceuticals worth $5,914,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Boxer Capital Management LLC acquired a new position in shares of Milestone Pharmaceuticals during the 4th quarter worth approximately $729,000. Virtu Financial LLC bought a new stake in shares of Milestone Pharmaceuticals during the fourth quarter worth $170,000. Northern Trust Corp increased its holdings in shares of Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company's stock worth $137,000 after buying an additional 30,772 shares in the last quarter. XTX Topco Ltd bought a new stake in Milestone Pharmaceuticals during the 4th quarter worth $80,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter worth $73,000. 86.18% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on MIST. TD Securities cut Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, April 1st. HC Wainwright reissued a "buy" rating and set a $25.00 target price on shares of Milestone Pharmaceuticals in a research note on Friday, March 28th. Cowen downgraded Milestone Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Finally, TD Cowen downgraded Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, April 1st. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $17.00.

Milestone Pharmaceuticals Stock Performance

Milestone Pharmaceuticals stock traded up $0.02 during midday trading on Wednesday, reaching $1.41. The stock had a trading volume of 413,911 shares, compared to its average volume of 892,661. The firm's 50-day moving average price is $1.24 and its 200 day moving average price is $1.71. Milestone Pharmaceuticals Inc. has a 12 month low of $0.63 and a 12 month high of $2.75. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $75.12 million, a PE ratio of -1.73 and a beta of 0.86.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.12). As a group, research analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current fiscal year.

Milestone Pharmaceuticals Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.